Please login to the form below

Not currently logged in


This page shows the latest hypertriglyceridaemia news and features for those working in and with pharma, biotech and healthcare.

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

hypertriglyceridaemia. The STRENGTH trial was viewed as being critical to expanding the market for the drug, whose sales hasn’t taken off as AZ had hoped since approval.

Latest news

  • FDA approves AZ’s fish oil drug FDA approves AZ’s fish oil drug

    The FDA approval covers its use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia. ... According to AZ, nearly four million adults in the US currently have severe hypertriglyceridaemia.

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    The US Food and Drug Administration (FDA) will assess Epanova for use in the treatment of patients with severe hypertriglyceridaemia – an excess of fatty molecules called triglycerides in the blood. ... By tackling triglycerides, these oils can have

  • FDA gives priority review status to BMS/ AZ's metreleptin FDA gives priority review status to BMS/ AZ's metreleptin

    Amylin filed for approval of metreleptin in 2010 as a treatment for diabetes and/or hypertriglyceridaemia in LD patients, using a rolling biologics license application (BLA) that allowed the various parts

  • Amylin and Takeda halt obesity drug study

    In late 2010, Amylin began submission of a rolling US Biologics Licensing Application for metreleptin as monotherapy to treat diabetes and/or hypertriglyceridaemia (high levels of triglycerides in the bloodstream) in

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...